Allogene Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2017
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2017
Revenue	0.02	0.1	0.16	114.09	-	Upgrade
Revenue Growth (YoY)	-76.84%	-39.10%	-99.86%	-	-	Upgrade
Cost of Revenue	192.3	242.91	256.39	220.18	192.99	Upgrade
Gross Profit	-192.28	-242.82	-256.23	-106.09	-192.99	Upgrade
Selling, General & Admin	65.21	71.67	79.31	74.11	65.26	Upgrade
Operating Expenses	65.21	71.67	79.31	74.11	65.26	Upgrade
Operating Income	-257.48	-314.49	-335.54	-180.19	-258.24	Upgrade
Interest Expense	-0.18	-	-	-	-	Upgrade
Interest & Investment Income	20.15	18.31	4.57	1.71	8.86	Upgrade
Earnings From Equity Investments	-1.69	-10.67	-12.88	-4.09	-67.31	Upgrade
Other Non Operating Income (Expenses)	-0.28	-0.16	3.44	0.52	0.31	Upgrade
EBT Excluding Unusual Items	-239.47	-307.02	-340.41	-182.05	-316.38	Upgrade
Gain (Loss) on Sale of Investments	-1.96	-7	-	-	-	Upgrade
Asset Writedown	-15.72	-13.25	-	-	-	Upgrade
Pretax Income	-257.15	-327.27	-340.41	-182.05	-316.38	Upgrade
Income Tax Expense	0.44	-	-	-	-	Upgrade
Net Income	-257.59	-327.27	-340.41	-182.05	-316.38	Upgrade
Net Income to Common	-257.59	-327.27	-340.41	-182.05	-316.38	Upgrade
Shares Outstanding (Basic)	195	157	143	136	120	Upgrade
Shares Outstanding (Diluted)	195	157	143	136	120	Upgrade
Shares Change (YoY)	24.14%	9.63%	5.39%	12.84%	19.11%	Upgrade
EPS (Basic)	-1.32	-2.09	-2.38	-1.34	-2.63	Upgrade
EPS (Diluted)	-1.32	-2.09	-2.38	-1.34	-2.63	Upgrade
Free Cash Flow	-200.99	-239.25	-225.71	-206.26	-181.05	Upgrade
Free Cash Flow Per Share	-1.03	-1.52	-1.58	-1.52	-1.50	Upgrade
Gross Margin	-	-	-	-92.99%	-	Upgrade
Operating Margin	-1170372.73%	-331044.21%	-215087.18%	-157.94%	-	Upgrade
Profit Margin	-1170863.64%	-344489.47%	-218214.10%	-159.57%	-	Upgrade
Free Cash Flow Margin	-913609.09%	-251841.05%	-144685.90%	-180.79%	-	Upgrade
EBITDA	-243.84	-300.29	-321.24	-169.74	-250.81	Upgrade
EBITDA Margin	-	-	-	-148.78%	-	Upgrade
D&A For EBITDA	13.64	14.2	14.3	10.45	7.44	Upgrade
EBIT	-257.48	-314.49	-335.54	-180.19	-258.24	Upgrade
EBIT Margin	-	-	-	-157.94%	-	Upgrade

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q